Alemtuzumab has been associated with infusion-related events including hypotension, rigors, fever, shortness of breath, bronchospasm, chills, and/or rash <ref>https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm082681.htm</ref>.

 


 
It can also precipitate [[autoimmune disease]] through the suppression of [[suppressor T cell]] populations and/or the emergence of autoreactive B-cells.<ref name=Costelloe2012>{{cite journal|last=Costelloe|first=L|author2=Jones J|author3=Coles A|title=Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis|journal=Expert Rev Neurother|date=March 2012|volume=12|issue=3|pages=335–41|doi=10.1586/ern.12.5|pmid=22364332}}</ref><ref name=Aranha2013>{{cite journal|last=Aranha|first=AA|author2=Amer S|author3=Reda ES|author4=Broadley SA|author5=Davoren PM|title=Autoimmune Thyroid Disease in the Use of Alemtuzumab for Multiple Sclerosis: A Review|journal=Endocrine Practice|date=Jun 11, 2013|volume=19|pages=1–25|doi=10.4158/EP13020.RA|pmid=23757618|issue=5}}</ref>

 

